A Children’s Oncology Group (COG) pediatric AML study (16) showed that CBFA2T3-GLIS2 fusion was cooperated with little recurrent mutations and upregulation of CD56, which was coordinated with our findings. This evidence concerns the gene GLIS2 and acute myeloid leukemia.